Traders Buy Large Volume of PDS Biotechnology Call Options (NASDAQ:PDSB)

PDS Biotechnology Corporation (NASDAQ:PDSB) saw unusually large options trading on Tuesday. Stock investors bought 1,957 call options on the company. This represents an increase of 1,154% compared to the typical volume of 156 call options.

Analysts Set New Price Targets

PDSB has been the topic of several research analyst reports. Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings upgraded shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Finally, HC Wainwright reissued a “buy” rating on shares of PDS Biotechnology in a report on Wednesday, August 26th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.00.

Hedge Funds Weigh In On PDS Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of PDSB. Virtu Financial LLC bought a new stake in PDS Biotechnology in the fourth quarter valued at $25,000. Geode Capital Management LLC boosted its stake in shares of PDS Biotechnology by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after purchasing an additional 38,399 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of PDS Biotechnology by 25.0% in the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after purchasing an additional 44,100 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of PDS Biotechnology in the 2nd quarter worth about $91,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of PDS Biotechnology during the 2nd quarter worth about $60,000. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Price Performance

Shares of NASDAQ:PDSB traded up $0.11 during midday trading on Tuesday, reaching $0.33. 332,200,471 shares of the company’s stock were exchanged, compared to its average volume of 2,553,967. The company has a debt-to-equity ratio of 2.73, a quick ratio of 0.57 and a current ratio of 0.57. The company’s 50 day simple moving average is $0.54 and its two-hundred day simple moving average is $0.79. PDS Biotechnology has a 12 month low of $0.20 and a 12 month high of $1.55. The firm has a market capitalization of $18.36 million, a PE ratio of -0.51 and a beta of 1.46.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Equities research analysts expect that PDS Biotechnology will post -0.45 earnings per share for the current fiscal year.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.